Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PDE1A | P54750 | 1/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19607847 | 0.96 | CYP3A4 (0.45) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607741 | 0.88 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607990 | 0.84 | GRM7 (0.44) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607729 | 0.84 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL25492179 | 0.84 | GAA (0.52) | CYP3A4CYP1A2CYP2C9ALDH1A1MAPT | |
| SCHEMBL19607901 | 0.83 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607897 | 0.81 | SSTR5 (0.40) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL29808290 | 0.81 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607886 | 0.81 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL19607909 | 0.81 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190144441-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144441-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3454897-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | Georgia State University Research Foundation, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017196982-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017196982-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | NIPSNAP3A, ZC3HAV1, SARNP | PDE4A 4316/4885PDE4B 3946/4885PDE4C 4633/4885 |
| US-20190144441-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV | NIPSNAP3A, ZC3HAV1, SARNP | PDE4A 4316/4885PDE4B 3946/4885PDE4C 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.